Attached files
| file | filename |
|---|---|
| EX-5.1 - OPINION OF LUCOSKY BROOKMAN LLP - MyMD Pharmaceuticals, Inc. | fs12017a1ex5-1_akersbiosci.htm |
| EX-3.7 - FORM OF CERTIFICATE OF SERIES B PREFERRED STOCK DESIGNATION - MyMD Pharmaceuticals, Inc. | fs12017a1ex3-7_akersbiosci.htm |
| S-1/A - AMENDMENT NO. 1 TO FORM S-1 - MyMD Pharmaceuticals, Inc. | fs12017a1_akersbiosciences.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 11, 2017, contained in the Annual Report on Form 10-K for Akers Biosciences, Inc., in the Registration Statement (S-1) dated December 8, 2017 and the related prospectus of Akers Biosciences, Inc. included therein.
| /s/ Morison Cogen LLP | |
| Blue Bell, Pennsylvania | |
| December 8, 2017 |